Hilltop National Bank Takes $341,000 Position in United Therapeutics Corporation $UTHR

Hilltop National Bank bought a new stake in United Therapeutics Corporation (NASDAQ:UTHR) in the second quarter, HoldingsChannel reports. The firm bought 1,187 shares of the biotechnology company’s stock, valued at approximately $341,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. increased its position in United Therapeutics by 0.3% during the 1st quarter. Vanguard Group Inc. now owns 4,457,135 shares of the biotechnology company’s stock valued at $1,374,001,000 after buying an additional 15,312 shares in the last quarter. Dimensional Fund Advisors LP increased its position in United Therapeutics by 0.7% during the 1st quarter. Dimensional Fund Advisors LP now owns 624,711 shares of the biotechnology company’s stock valued at $192,571,000 after buying an additional 4,145 shares in the last quarter. Assetmark Inc. increased its position in United Therapeutics by 20.8% during the 1st quarter. Assetmark Inc. now owns 518,450 shares of the biotechnology company’s stock valued at $159,823,000 after buying an additional 89,290 shares in the last quarter. Caisse DE Depot ET Placement DU Quebec increased its position in United Therapeutics by 22.5% during the 1st quarter. Caisse DE Depot ET Placement DU Quebec now owns 477,757 shares of the biotechnology company’s stock valued at $147,278,000 after buying an additional 87,664 shares in the last quarter. Finally, Invesco Ltd. increased its position in United Therapeutics by 46.1% during the 1st quarter. Invesco Ltd. now owns 465,115 shares of the biotechnology company’s stock valued at $143,381,000 after buying an additional 146,664 shares in the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Insider Buying and Selling

In related news, EVP Paul A. Mahon sold 11,000 shares of United Therapeutics stock in a transaction on Thursday, October 2nd. The stock was sold at an average price of $436.60, for a total value of $4,802,600.00. Following the completion of the sale, the executive vice president owned 36,781 shares of the company’s stock, valued at $16,058,584.60. The trade was a 23.02% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Christopher Causey sold 1,000 shares of United Therapeutics stock in a transaction on Wednesday, September 24th. The stock was sold at an average price of $440.00, for a total value of $440,000.00. Following the completion of the sale, the director directly owned 4,865 shares of the company’s stock, valued at $2,140,600. The trade was a 17.05% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 238,435 shares of company stock valued at $93,353,482 over the last ninety days. 10.30% of the stock is owned by insiders.

United Therapeutics Trading Up 2.2%

United Therapeutics stock opened at $453.07 on Friday. United Therapeutics Corporation has a 12 month low of $266.98 and a 12 month high of $455.12. The firm has a market cap of $20.44 billion, a price-to-earnings ratio of 17.68, a PEG ratio of 6.76 and a beta of 0.66. The stock has a fifty day simple moving average of $356.31 and a two-hundred day simple moving average of $319.01.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, July 30th. The biotechnology company reported $6.41 EPS for the quarter, missing the consensus estimate of $6.80 by ($0.39). United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%.The firm had revenue of $798.60 million during the quarter, compared to the consensus estimate of $802.13 million. During the same period in the previous year, the firm earned $5.85 EPS. The business’s revenue was up 11.7% on a year-over-year basis. On average, equities research analysts forecast that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the company. Jefferies Financial Group raised their price objective on United Therapeutics from $432.00 to $564.00 and gave the company a “buy” rating in a research report on Tuesday, September 2nd. Morgan Stanley reduced their price objective on United Therapeutics from $348.00 to $328.00 and set an “equal weight” rating for the company in a research report on Thursday, July 10th. UBS Group raised their price objective on United Therapeutics from $560.00 to $580.00 and gave the company a “buy” rating in a research report on Monday. Royal Bank Of Canada assumed coverage on United Therapeutics in a research report on Friday, September 26th. They set an “outperform” rating and a $569.00 price objective for the company. Finally, Wells Fargo & Company lifted their target price on United Therapeutics from $295.00 to $414.00 and gave the stock an “equal weight” rating in a report on Wednesday, September 3rd. Ten investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $449.57.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.